diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM20143122-128diaendo-6558Research ArticleОфтальмологияOphthalmologyСовременные возможности терапии диабетической ретинопатииCurrent approaches to the management of diabetic retinopathyДемидоваТатьяна ЮльевнаDemidovaTatiana Yul'evna

доктор медицинских наук, профессор кафедры эндокринологии и диабетологии

MD, PhD, professor, Department of Endocrinology and Diabetology

t.y.demidova@gmail.comТрахтенбергЮлия АлександровнаTrakhtenbergYulia Alexandrovna

кандидат медицинских наук, врач-эндокринолог

MD, PhD, «Center for Perinatal Prophylaxis» LLC

julia.trakhtenberg@mail.ruГБОУ ДПО Российская медицинская академия последипломного образования, МоскваРоссияRussian Medical Academy of Postdegree Education, MoscowRussian FederationООО «Центр перинатальной профилактики», МоскваРоссияCenter of Perinatal Care, MoscowRussian Federation201414062014173122128Copyright © Демидова Т.Ю., Трахтенберг Ю.А., 20142014Демидова Т.Ю., Трахтенберг Ю.А.Demidova T.Y., Trakhtenberg Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/6558

Статья отражает современное состояние проблемы терапии диабетической ретинопатии: представлены данные наиболее крупных исследований по эпидемиологии, скринингу, изучению факторов риска ДР. Представлены современные подходы к лечению ДР, перечень основных лекарственных препаратов, применяемых в данной области; описаны подробные сведения о фенофиброевой кислоте, механизме ее действия и опыте применения по данным литературы; описание средств для интравитреального введения, тормозящих рост новообразованных сосудов в сетчатке.

This review reflects the current status of the diabetic retinopathy treatment problem and describes the results of the largest trials on epidemiology, screening and the risk factors for complications. In addition, this article describes the current approaches and treatment options for diabetic retinopathy, including a description of fenofibroic acid with its mechanism of action and data from clinical trials. This article also contains information on antiangiogenic agents for intravitreal administration.

диабетическая ретинопатияфакторы рискадиабетический макулярный отекфактор роста эндотелия сосудовфенофиброевая кислотаdiabetic retinopathyrisk factorsdiabetic macular oedemaVEGFfenofibroic acidReferencesNational Diabetes Statistics, 2011. National Diabetes Information Clearinghouse; 2011. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/dm_statistics.pdfNational Diabetes Statistics, 2011. National Diabetes Information Clearinghouse; 2011. Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/dm_statistics.pdfKlein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. Ophthalmology 1995;102(1):7-16. doi: 10.1016/S0161-6420(95)31052-4.Klein R, Klein BEK, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV. Ophthalmology 1995;102(1):7-16. doi: 10.1016/S0161-6420(95)31052-4.Kohner EM. Diabetic retinopathy: preventing blindness in the 1990's. Diabetologia 1991;34(11):844-845. doi: 10.1007/BF00408363.Kohner EM. Diabetic retinopathy: preventing blindness in the 1990's. Diabetologia 1991;34(11):844-845. doi: 10.1007/BF00408363.Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32(12):2307-2313. doi: 10.2337/dc09-0615.Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32(12):2307-2313. doi: 10.2337/dc09-0615.Public Health Screening Programmes Annual Report 2011-2012.. National Health Service Greater Glasgow and Clyde; 2013. p 121-133. Available from: http://library.nhsggc.org.uk/mediaAssets/Public%20Health%20Screening/PHSU%20annual%20report%202011-12%20final.pdfPublic Health Screening Programmes Annual Report 2011-2012.. National Health Service Greater Glasgow and Clyde; 2013. p 121-133. Available from: http://library.nhsggc.org.uk/mediaAssets/Public%20Health%20Screening/PHSU%20annual%20report%202011-12%20final.pdfDodson P. Diabetic Retinopathy: Screening to treatment. Oxford diabetes library. Oxford University Press; 2009.Dodson P. Diabetic Retinopathy: Screening to treatment. Oxford diabetes library. Oxford University Press; 2009.Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LPAUL, Aiello LM. Use of Joslin vision network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. Retina.2003;23(2):215-223. doi: 10.1097/00006982-200304000-00013.Cavallerano AA, Cavallerano JD, Katalinic P, Tolson AM, Aiello LPAUL, Aiello LM. Use of Joslin vision network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program. Retina.2003;23(2):215-223. doi: 10.1097/00006982-200304000-00013.Шадричев ФЕ, Астахов ЮС, Григорьева НН, Шкляров ЕБ, Александрова ОН, Крянева ОЯ, и др. Эпидемиологические аспекты поражения сетчатки при сахарном диабете (результаты скрининга диабетической ретинопатии в Санкт-Петербурге). Офтальмологические Ведомости. 2009;2(4):13–18. [Shadrichev FE, Astakhov YuS, Grigor'eva NN, Shklyarov EB, Aleksandrova ON, Kryaneva OYa, et al. Epidemiologic aspects of retinal damage in diabetes mellius (diabetic retinopathy screening results in saint-petersburg). Oftalmologičeskie vedomosti. 2009;2(4):13–18.]Шадричев ФЕ, Астахов ЮС, Григорьева НН, Шкляров ЕБ, Александрова ОН, Крянева ОЯ, и др. Эпидемиологические аспекты поражения сетчатки при сахарном диабете (результаты скрининга диабетической ретинопатии в Санкт-Петербурге). Офтальмологические Ведомости. 2009;2(4):13–18. [Shadrichev FE, Astakhov YuS, Grigor'eva NN, Shklyarov EB, Aleksandrova ON, Kryaneva OYa, et al. Epidemiologic aspects of retinal damage in diabetes mellius (diabetic retinopathy screening results in saint-petersburg). Oftalmologičeskie vedomosti. 2009;2(4):13–18.]Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией Дедова ИИ, Шестаковой МВ (6-й выпуск). Сахарный диабет. 2013;(1s):1-121. [Dedov I, Shestakova M, Aleksandrov A, Galstyan G, Grigoryan O, Esayan R, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;(1S):1-120.] doi: 10.14341/DM20131S1-121Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией Дедова ИИ, Шестаковой МВ (6-й выпуск). Сахарный диабет. 2013;(1s):1-121. [Dedov I, Shestakova M, Aleksandrov A, Galstyan G, Grigoryan O, Esayan R, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV (6th edition). Diabetes mellitus. 2013;(1S):1-120.] doi: 10.14341/DM20131S1-121The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/NEJM199309303291401The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. doi: 10.1056/NEJM199309303291401UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28-31. doi:10.1016/S0140-6736(97)06209-0Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351(9095):28-31. doi:10.1016/S0140-6736(97)06209-0Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29(4):284-311. doi: 10.1016/j.preteyeres.2010.03.003Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29(4):284-311. doi: 10.1016/j.preteyeres.2010.03.003Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394-1402. doi: 10.1016/S0140-6736(08)61412-9Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372(9647):1394-1402. doi: 10.1016/S0140-6736(08)61412-9Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care. 2011;34(8):1838-1842. doi: 10.2337/dc11-0476Harindhanavudhi T, Mauer M, Klein R, Zinman B, Sinaiko A, Caramori ML. Benefits of Renin-Angiotensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care. 2011;34(8):1838-1842. doi: 10.2337/dc11-0476Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112(4):385-391.Gordon B, Chang S, Kavanagh M, Berrocal M, Yannuzzi L, Robertson C, et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol. 1991;112(4):385-391.Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology. 1995;102(1):7-16.Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114(9):1079-1084. doi:10.1001/archopht.1996.01100140281004Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol. 1996;114(9):1079-1084. doi:10.1001/archopht.1996.01100140281004Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol. 2008;102(12A):34L-40L. doi: 10.1016/j.amjcard.2008.09.073Sacks FM. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. Am J Cardiol. 2008;102(12A):34L-40L. doi: 10.1016/j.amjcard.2008.09.073ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244. doi: 10.1056/NEJMoa1001288ACCORD Study Group; ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244. doi: 10.1056/NEJMoa1001288Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968-3975. doi: 10.2337/db13-0800Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes. 2013;62(12):3968-3975. doi: 10.2337/db13-0800Simó R, García-Ramírez M, Higuera M, Hernández C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol. 2009;147(2):319-325.e1. doi: 10.1016/j.ajo.2008.08.009Simó R, García-Ramírez M, Higuera M, Hernández C. Apolipoprotein A1 is overexpressed in the retina of diabetic patients. Am J Ophthalmol. 2009;147(2):319-325.e1. doi: 10.1016/j.ajo.2008.08.009Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, et al. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261-272. doi: 10.2337/db11-0413Chen Y, Hu Y, Lin M, Jenkins AJ, Keech AC, Mott R, et al. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models. Diabetes. 2013;62(1):261-272. doi: 10.2337/db11-0413Schwartz SG, Flynn HW, Scott IU. Emerging Therapies for Diabetic Macular Edema. Expert Rev Ophthalmol. 2009;4(2):163-171. Available from: http://www.medscape.com/viewarticle/704734Schwartz SG, Flynn HW, Scott IU. Emerging Therapies for Diabetic Macular Edema. Expert Rev Ophthalmol. 2009;4(2):163-171. Available from: http://www.medscape.com/viewarticle/704734Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012;37(8):661-670. doi: 10.3109/02713683.2012.675616Wang H, Sun X, Liu K, Xu X. Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema: a systematic review and meta-analysis of randomized clinical control trials. Curr Eye Res. 2012;37(8):661-670. doi: 10.3109/02713683.2012.675616Do DV. Intravitreal afliberept injection (IAI) for diabetic macular edema (DME): 12-month results of VISTA-DME and VIVID-DME. Proceedings of the 2013 Annual Meeting of the American Academy of Ophthalmology; 2013 November 16-19, New Orleans.Do DV. Intravitreal afliberept injection (IAI) for diabetic macular edema (DME): 12-month results of VISTA-DME and VIVID-DME. Proceedings of the 2013 Annual Meeting of the American Academy of Ophthalmology; 2013 November 16-19, New Orleans.Kiire CA, Porta M, Chong V. Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol. 2013;58(5):459-65. doi: 10.1016/j.survophthal.2012.10.002Kiire CA, Porta M, Chong V. Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol. 2013;58(5):459-65. doi: 10.1016/j.survophthal.2012.10.002

The authors declare that there are no conflicts of interest present.